UPTRAVI (SELEXIPAG) HAS BEEN REGISTERED IN THE RUSSIAN FEDERATION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULT PATIENTS
.
Saved in:
| Main Author: | article Editorial |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2019-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Online Access: | https://www.heartj.asia/jour/article/view/352 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What has been achieved and what has not been achieved in 2020
by: article Editorial
Published: (2021-04-01) -
FEATURES OF PULMONARY ARTERIAL HYPERTENSION IN THE RUSSIAN REGISTER
by: O. A. Arkhipova, et al.
Published: (2014-12-01) -
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01) -
Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study)
by: Stefan Söderberg, et al.
Published: (2025-04-01) -
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
by: E. A. Rezukhina, et al.
Published: (2023-03-01)